Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized adjuvant chemotherapy after CRS and HIPEC for diffuse malignant peritoneal mesothelioma
2012-000382-20Phase 2Completed
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Jan 2013
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cisplatin, pemetrexed, doxorubicin, gemcitabine and vinorelbine in diffuse malignant peritoneal mesothelioma (DMPM) and peritoneal mesothelioma, sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: progression-free survival. Started Jan 2013; status: completed.
02
Drugs
cisplatinpemetrexeddoxorubicingemcitabinevinorelbine
03
Conditions
diffuse malignant peritoneal mesothelioma (DMPM)peritoneal mesothelioma
Beyond the preview
Go deeper on 2012-000382-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000382-20.